Original ArticlesA pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis☆,☆☆,★,★★
Section snippets
Patients
Adult patients with a documented diagnosis of UC were recruited from the University of Chicago Outpatient Gastroenterology Clinic. To be eligible, patients were required to have been in clinical remission (defined as the absence of blood in the stools, urgency, or cramping) for at least 4 months before entry into the study and to be receiving mesalamine for maintenance of quiescent disease. Exclusion criteria included documented disease activity in the past 4 months, hospitalization or steroid
Results
Twenty-two patients with quiescent UC were enrolled over a 3-month period. All patients had appropriate documentation of mesalamine use before randomization. Follow-up was complete on all 22 patients. Patient demographics and disease characteristics are summarized in Table 1.
Empty Cell Treatment group Empty Cell Variable Once daily Conventional P value Sex (M/F) 2/10 2/8 P > 0.05 Age (yr) 46.2 ± 13.4 37.3 ± 15.5 P > 0.05 Dose (g/day) 2.5 ± 0.9 2.7 ± 0.8 P > 0.05 Time in remission (mo) 10.1 ± 3.0 9.6 ± 3.7 P >
Discussion
In this small pilot and feasibility study, the number of clinical relapses after 6 months was similar in the QD and CD mesalamine treatment groups. The adherence rates were also similar after this time period, although patients in the QD group consumed more medication overall and appeared more satisfied with this regimen.
Data from maintenance trials suggest that 1.6 g is a sufficient dosage to maintain quiescent UC.6 In a QD regimen, this would equate to taking only 4 tablets once a day to
References (19)
- et al.
Cigarette smoking and ulcerative colitis: a case control study
Mayo Clin Proc
(1994) - et al.
Effect of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: a case-control study
Am J Gastroenterol
(2000) - et al.
Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission
Am J Gastroenterol
(2000) - et al.
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
Am J Gastroenterol
(2001) - et al.
Increasing patient adherence to gastrointestinal treatment and prevention regimens
Am J Gastroenterol
(1999) - et al.
Studies on the mechanism of bowel disturbance in ulcerative colitis
Gastroenterology
(1987) - et al.
A simple index of Crohn's disease activity (abstr)
Lancet
(1980) - et al.
The optimal dose of 5-aminosalicyclic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine
Clin Gastroenterol Hepatol
(2003) - et al.
Effects of smoking on the presentation and clinical course of inflammatory bowel disease
Eur J Gastroenterol Hepatol
(1997)
Cited by (109)
Inflammatory bowel disease and gastrointestinal disorders
2020, Adherence and Self-Management in Pediatric PopulationsAGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis
2019, GastroenterologyCitation Excerpt :In patients with mild–moderate UC treated with oral mesalamine, there is probably no difference between equivalent doses of mesalamine administered once daily vs multiple times per day for inducing and maintaining remission (moderate-quality evidence). We identified 4 trials comparing equivalent doses of mesalamine administered once daily vs multiple times per day (2 or more divided doses) for induction of remission,37,40,131,132 and 11 trials comparing different mesalamine dosing schema for maintenance of remission, in patients with mild–moderate UC.60,62,133–141 All studies used standard-dose mesalamine; no trials of once-daily administration of diazo-bonded 5-ASA or sulfasalazine were identified.
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)
2015, Revista de Gastroenterologia de MexicoPractice guidelines for (version longue) the diagnosis and management of ulcerative colitis
2022, Hepato-Gastro et Oncologie DigestiveClinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD
2021, Inflammatory Bowel Diseases
- ☆
Address requests for reprints to: Sunanda Kane, M.D., M.S.P.H., 5841 South Maryland Avenue, MC 4076, Chicago, Illinois 60637. e-mail: [email protected]; fax: (773) 702-2182.
- ☆☆
Supported in part by a grant from Procter & Gamble Pharmaceuticals and the David and Reva Logan Center for Gastrointestinal Research.
- ★
Dr. Kane serves as a consultant to Procter & Gamble Pharmaceuticals, Shire Pharmaceuticals, and Salix Pharmaceuticals, as well as on the Speaker Bureau for all of these companies.
- ★★
1542-3565/03/$30.00